Effect of tiopronin combined with rosiglitazone on non-alcoholic fatty liver disease

Objective To observe the efficacy of tiopronin combined with rosiglitazone on non-alcoholic fatty liver disease(NAFLD) and its influence on regulatory T cells. Methods A total of 100 patients with NAFLD were randomly divided into treatment group and control group with 50 cases in each. The treatment group were treated with tiopronin200 mg Bid and rosiglitazone 2 mg Bid. The control group were treated with liver-protecting tablet 1.5 g Tid. The efficacy,liver function, blood fat, insulin resistance index(HOMA-IR) and regulatory T cells were observed at 3 months after treatment. Results The levels of serum alanine aminotransferase and aspartate aminotransferase of two groups were significantly lower than those pre-treatment(t=31.81,17.94,20.31,14.86,P0.05). After treatment, the levels of serum triglycerides, total cholesterol, low-density lipoprotein cholesterol and HOMA-IR in treatment group were significantly decreased, and high-density lipoprotein cholesterol levels were significantly increased, the differences were statistically significant(t=6.84,8.81,7.59,7.41,P0.05) while only serum TG and TC in the control group was significantly decrease(t=4.71,4.96,P0.05). After treatment, the fatty liver degree of type-B ultrasonic in treatment group was significantly lower than that in control group(Z=2.56,P0.05). The total efficiency of the treatment group(92.00%) was significantly higher than that of the control group(67.10%), the difference was statistically significant(χ2=10.07,P0.05). Compared with control group, the CD4+CD25+/CD4+ratio and CD4+CD25+Foxp3/CD4+ratio were significantly increased in the treatment group, the differences were statistically significant(t=4.78,6.74,P0.05). Conclusion The effect of tiopronin combined with rosiglitazone on NAFLD has notable curative in reducing blood lipit and insulin resistance and improving liver function.